Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab and Umbralisib Add-on in CLL
NCT04016805Phase 2Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Aug 2019
- Primary completion
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ublituximab, umbralisib in chronic lymphocytic leukemia (CLL), sponsored by TG Therapeutics, Inc.. Started Aug 2019; status: terminated.
02
Drugs
ublituximabumbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04016805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04016805.